Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Grant Life Sciences has agreed to exclusively in-license the manufacturing and marketing rights to Alphagenics Diaco's molecular diagnostic test for human papillomaviruses in China and the US, and non-exclusively in all other countries.
Subscribe to our email newsletter
The Alphagenics human papillomaviruses (HPV) test in-licensed by Grant is a DNA-based diagnostic that uses standard molecular diagnostic equipment found in most commercial laboratories. Alphagenics Diaco’s HPV DNA test complements the HPV blood test that Grant has been developing to detect the presence of antibodies produced only by cancer-causing HPV types.
Grant expects to launch the Alphagenics HPV DNA-based test in the Asian and Indian markets during the first quarter of 2008 as an analyte-specific reagent (ASR) to reference laboratories.
Grant added that the Alphagenics test could be used by women to determine if they have been exposed to the HPV virus, and evaluate the possible use of a HPV vaccine if found negative.
Hun-Chi Lin, president and chief scientist, Grant Life Sciences, said: “Our introduction of the Alphagenics HPV test not only will allow commercial laboratories to provide molecular testing but will also complement the current introduction of vaccines against HPVs. The Alphagenics test is designed to test for all the serotypes of oncogenic HPV.”